 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_extracts) FUNC: {
  "name": "relevant_extracts",
  "to": "",
  "arguments": {
    "query": "Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "filter_drugs": [
      "PHENYTOIN"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: PHENYTOIN: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using 
alternative antiepileptic drugs. 5.8 Local Toxicity (Including Purple Glove Syndrome) Soft tissue irritation and inflammation has occurred at the site of injection with and without extravasation of 
intravenous phenytoin. Edema, discoloration and pain distal to the site of injection (described as “purple glove syndrome”) have also been reported following peripheral intravenous phenytoin 
injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for several days after injection. Although resolution of symptoms 
may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN: warnings_and_cautions: 
Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through a large-gauge catheter. Prior to the 
administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then be followed by a flush of sterile 
saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration may cause pain, necrosis, and 
abscess formation at the injection site  . 5. PHENYTOIN: warnings_and_cautions: 9 Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with
renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. 5.10 Exacerbation of Porphyria In view 
of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this disease. 5.11 Teratogenicity and Other 
Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other 
adverse developmental outcomes  . PHENYTOIN: warnings_and_cautions: Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), and abnormalities characteristic of 
fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits, have been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including 
neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This 
drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. 5.12 Hyperglycemia Hyperglycemia, resulting from the drug's 
inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic patients. 5.13 Serum Phenytoin Levels Above 
Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as "delirium", "psychosis", or "encephalopathy", or rarely irreversible 
cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction of phenytoin therapy is indicated if 
serum levels are excessive; if symptoms persist, termination is recommended.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: pregnancy: 8.1 Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such 
as Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.
This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website 
http://www.aedpregnancyregistry.org/ . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal 
phenytoin exposure is associated with an increased incidence of major malformations (including orofacial clefts and cardiac defects). PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a 
pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits has been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy  . There have been several reported cases of malignancies, including 
neuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other 
manifestations of developmental toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses . In the U.S. general 
population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. PHENYTOIN: pregnancy: The background 
risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during 
pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment
of dosage  . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased 
levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before 
delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately 2. PHENYTOIN: pregnancy: 4-fold 
increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been 
reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental 
deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth 
retardation. Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, 
respectively.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: package_ndc         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: product_ndc         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: spl_id         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: geriatric_use: 8.5 Geriatric Use Phenytoin clearance tends to decrease with increasing age  . Lower or less frequent dosing may be required .         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: information_for_patients: 17 PATIENT COUNSELING INFORMATION W ithdrawal of Antiepileptic Drugs Advise patients not to discontinue use of phenytoin without consulting with their 
healthcare provider. Phenytoin should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus  . P otential Signs of Drug Reaction with 
Eosinophilia and Systemic Symptoms (DRESS) and Other Systemic R eac tions Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and
in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. PHENYTOIN: information_for_patients: Advise the patient that, because these signs and symptoms may signal a serious reaction, 
that they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use  . 
Effects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions Caution patients against the use of other drugs or alcoholic beverages without first seeking their physician’s advice  . 
Inform patients that certain over-the-counter medications (e.g., cimetidine and omeprazole), vitamins (e.g., folic acid), and herbal supplements (e.g., St. PHENYTOIN: information_for_patients: John’s 
wort) can alter their phenytoin levels. Hyperglycemia Advise patients that phenytoin may cause an increase in blood glucose levels  . Gingival Hyperplasia Advise patients of the importance of good 
dental hygiene in order to minimize the development of gingival hyperplasia and its complications. Neurologic Effects Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased 
coordination and somnolence. Advise patients taking phenytoin not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects 
associated with phenytoin. PHENYTOIN: information_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, 
including an increased risk for cleft lip and/or cleft palate (oral clefts), cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including 
microcephaly), and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who 
are not planning a pregnancy to use effective contraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy . Instruct patients to notify
their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy  . PHENYTOIN: 
information_for_patients: Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the 
safety of antiepileptic drugs during pregnancy  . Manufactured by: Hikma Pharmaceuticals USA Inc.         
SOURCE:PHENYTOIN label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          )  DO-NOT-KNOW
*(FDAHandler)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "drug": "PHENYTOIN"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does PHENYTOIN increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does PHENYTOIN increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "drug": "PHENYTOIN"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
CONTENT: PHENYTOIN: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using 
alternative antiepileptic drugs. 5.8 Local Toxicity (Including Purple Glove Syndrome) Soft tissue irritation and inflammation has occurred at the site of injection with and without extravasation of 
intravenous phenytoin. Edema, discoloration and pain distal to the site of injection (described as “purple glove syndrome”) have also been reported following peripheral intravenous phenytoin 
injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for several days after injection. Although resolution of symptoms 
may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN: warnings_and_cautions: 
Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through a large-gauge catheter. Prior to the 
administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then be followed by a flush of sterile 
saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration may cause pain, necrosis, and 
abscess formation at the injection site  . 5. PHENYTOIN: warnings_and_cautions: 9 Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with
renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. 5.10 Exacerbation of Porphyria In view 
of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this disease. 5.11 Teratogenicity and Other 
Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other 
adverse developmental outcomes  . PHENYTOIN: warnings_and_cautions: Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), and abnormalities characteristic of 
fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits, have been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including 
neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This 
drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. 5.12 Hyperglycemia Hyperglycemia, resulting from the drug's 
inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic patients. 5.13 Serum Phenytoin Levels Above 
Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as "delirium", "psychosis", or "encephalopathy", or rarely irreversible 
cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction of phenytoin therapy is indicated if 
serum levels are excessive; if symptoms persist, termination is recommended.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: pregnancy: 8.1 Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such 
as Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.
This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website 
http://www.aedpregnancyregistry.org/ . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal 
phenytoin exposure is associated with an increased incidence of major malformations (including orofacial clefts and cardiac defects). PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a 
pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits has been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy  . There have been several reported cases of malignancies, including 
neuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other 
manifestations of developmental toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses . In the U.S. general 
population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. PHENYTOIN: pregnancy: The background 
risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during 
pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment
of dosage  . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased 
levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before 
delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately 2. PHENYTOIN: pregnancy: 4-fold 
increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been 
reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental 
deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth 
retardation. Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, 
respectively.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: package_ndc         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: product_ndc         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: spl_id         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: geriatric_use: 8.5 Geriatric Use Phenytoin clearance tends to decrease with increasing age  . Lower or less frequent dosing may be required .         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: information_for_patients: 17 PATIENT COUNSELING INFORMATION W ithdrawal of Antiepileptic Drugs Advise patients not to discontinue use of phenytoin without consulting with their 
healthcare provider. Phenytoin should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus  . P otential Signs of Drug Reaction with 
Eosinophilia and Systemic Symptoms (DRESS) and Other Systemic R eac tions Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and
in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. PHENYTOIN: information_for_patients: Advise the patient that, because these signs and symptoms may signal a serious reaction, 
that they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use  . 
Effects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions Caution patients against the use of other drugs or alcoholic beverages without first seeking their physician’s advice  . 
Inform patients that certain over-the-counter medications (e.g., cimetidine and omeprazole), vitamins (e.g., folic acid), and herbal supplements (e.g., St. PHENYTOIN: information_for_patients: John’s 
wort) can alter their phenytoin levels. Hyperglycemia Advise patients that phenytoin may cause an increase in blood glucose levels  . Gingival Hyperplasia Advise patients of the importance of good 
dental hygiene in order to minimize the development of gingival hyperplasia and its complications. Neurologic Effects Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased 
coordination and somnolence. Advise patients taking phenytoin not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects 
associated with phenytoin. PHENYTOIN: information_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, 
including an increased risk for cleft lip and/or cleft palate (oral clefts), cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including 
microcephaly), and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who 
are not planning a pregnancy to use effective contraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy . Instruct patients to notify
their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy  . PHENYTOIN: 
information_for_patients: Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the 
safety of antiepileptic drugs during pregnancy  . Manufactured by: Hikma Pharmaceuticals USA Inc.         
SOURCE:PHENYTOIN label

 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does phenytoin increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "drug": "phenytoin"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does phenytoin increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does phenytoin increase or decrease the risk of 
gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does phenytoin increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "drug": "phenytoin"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
CONTENT: PHENYTOIN: information_for_patients: 17 PATIENT COUNSELING INFORMATION W ithdrawal of Antiepileptic Drugs Advise patients not to discontinue use of phenytoin without consulting with their 
healthcare provider. Phenytoin should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus  . P otential Signs of Drug Reaction with 
Eosinophilia and Systemic Symptoms (DRESS) and Other Systemic R eac tions Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and
in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. PHENYTOIN: information_for_patients: Advise the patient that, because these signs and symptoms may signal a serious reaction, 
that they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use  . 
Effects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions Caution patients against the use of other drugs or alcoholic beverages without first seeking their physician’s advice  . 
Inform patients that certain over-the-counter medications (e.g., cimetidine and omeprazole), vitamins (e.g., folic acid), and herbal supplements (e.g., St. PHENYTOIN: information_for_patients: John’s 
wort) can alter their phenytoin levels. Hyperglycemia Advise patients that phenytoin may cause an increase in blood glucose levels  . Gingival Hyperplasia Advise patients of the importance of good 
dental hygiene in order to minimize the development of gingival hyperplasia and its complications. Neurologic Effects Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased 
coordination and somnolence. Advise patients taking phenytoin not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects 
associated with phenytoin. PHENYTOIN: information_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, 
including an increased risk for cleft lip and/or cleft palate (oral clefts), cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including 
microcephaly), and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who 
are not planning a pregnancy to use effective contraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy . Instruct patients to notify
their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy  . PHENYTOIN: 
information_for_patients: Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the 
safety of antiepileptic drugs during pregnancy  . Manufactured by: Hikma Pharmaceuticals USA Inc.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using 
alternative antiepileptic drugs. 5.8 Local Toxicity (Including Purple Glove Syndrome) Soft tissue irritation and inflammation has occurred at the site of injection with and without extravasation of 
intravenous phenytoin. Edema, discoloration and pain distal to the site of injection (described as “purple glove syndrome”) have also been reported following peripheral intravenous phenytoin 
injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for several days after injection. Although resolution of symptoms 
may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN: warnings_and_cautions: 
Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through a large-gauge catheter. Prior to the 
administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then be followed by a flush of sterile 
saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration may cause pain, necrosis, and 
abscess formation at the injection site  . 5. PHENYTOIN: warnings_and_cautions: 9 Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with
renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. 5.10 Exacerbation of Porphyria In view 
of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this disease. 5.11 Teratogenicity and Other 
Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other 
adverse developmental outcomes  . PHENYTOIN: warnings_and_cautions: Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), and abnormalities characteristic of 
fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits, have been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including 
neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This 
drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. 5.12 Hyperglycemia Hyperglycemia, resulting from the drug's 
inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic patients. 5.13 Serum Phenytoin Levels Above 
Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as "delirium", "psychosis", or "encephalopathy", or rarely irreversible 
cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction of phenytoin therapy is indicated if 
serum levels are excessive; if symptoms persist, termination is recommended.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: geriatric_use: 8.5 Geriatric Use Phenytoin clearance tends to decrease with increasing age  . Lower or less frequent dosing may be required .         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: adverse_reactions: 8) ] Exacerbation of Porphyria  Teratogenicity and Other Harm to the Newborn  Hyperglycemia  The following adverse reactions associated with the use of Phenytoin
Sodium Injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to 
reliably estimate their frequency or establish a causal relationship to drug exposure. The most notable signs of toxicity associated with the intravenous use of this drug are cardiovascular collapse 
and/or CNS depression. Hypotension does occur when the drug is administered rapidly by the intravenous route. PHENYTOIN: adverse_reactions: The rate of administration is very important; it should not 
exceed 50 mg per minute in adults, and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients  . Body As a Whole: Allergic reactions in the form of rash and rarely more 
serious forms (see Skin and Appendages paragraph below) and DRESS  have been observed. Anaphylaxis has also been reported. There have also been reports of coarsening of facial features, systemic lupus
erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe cardiovascular events and fatalities have been reported with atrial and ventricular conduction depression 
and ventricular fibrillation. PHENYTOIN: adverse_reactions: Severe complications are most commonly encountered in elderly or critically ill patients  . Digestive System: Acute hepatic failure  , toxic
hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally
been reported in association with administration of phenytoin  . These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow 
suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. PHENYTOIN: adverse_reactions: Lymphadenopathy, including benign lymph 
node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease have been reported . Laboratory Test Abnormality: Phenytoin may decrease serum concentrations of thyroid hormone (T4 and T3), 
sometimes with an accompanying increase in thyroid-stimulating hormone (TSH), but usually in the absence of clinical hypothyroidism. Phenytoin may also produce lower than normal values for 
dexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of glucose , alkaline phosphatase, and gamma glutamyl transpeptidase (GGT). Nervous System: The most common adverse 
reactions encountered with phenytoin therapy are nervous system reactions and are usually dose-related. PHENYTOIN: adverse_reactions: Reactions include nystagmus, ataxia, slurred speech, decreased 
coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor twitchings, paresthesia, and headaches have also been observed. There have also been rare 
reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs. Cerebellar atrophy has been reported,
and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use  . A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term 
phenytoin therapy. Sk in and Appendages: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: pregnancy: 8.1 Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such 
as Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.
This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website 
http://www.aedpregnancyregistry.org/ . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal 
phenytoin exposure is associated with an increased incidence of major malformations (including orofacial clefts and cardiac defects). PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a 
pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits has been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy  . There have been several reported cases of malignancies, including 
neuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other 
manifestations of developmental toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses . In the U.S. general 
population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. PHENYTOIN: pregnancy: The background 
risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during 
pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment
of dosage  . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased 
levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before 
delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately 2. PHENYTOIN: pregnancy: 4-fold 
increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been 
reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental 
deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth 
retardation. Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, 
respectively.         
SOURCE:PHENYTOIN label

 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

Justification:
I attempted to obtain information from FDAHandler regarding the effect of phenytoin on the risk of gastrointestinal ulcer hospitalization. However, it seems that there was an issue with the 
communication, and I was unable to receive the necessary data to provide an informed answer. Without specific information from FDA label data, I cannot determine whether phenytoin increases or 
decreases the risk of gastrointestinal ulcer hospitalization. Therefore, my final answer is that I do not know.
